What happened with ADPT today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Adaptive Biotechnologies helps doctors measure how much cancer remains during treatment or remission. Its clonoSEQ test identifies genetic sequences associated with a patient’s cancer and tracks them in later samples to measure minimal residual disease, or MRD. This business supplies most of the company’s revenue. Doctors order the tests and receive reports; the company bills private insurers, government healthcare programs and medical institutions, with patients sometimes responsible for part of the cost. Biopharmaceutical companies also pay to use clonoSEQ in drug development.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Natera and Adaptive both benefit when clinicians and biopharma researchers adopt tests that track cancer remaining after treatment, or MRD, and payers cover them, though Signatera and clonoSEQ focus on different cancers. Watch Signatera adoption and reimbursement for clues to demand and payment for cancer monitoring.
Personalis, Inc. and Adaptive sell tests that monitor residual cancer to physicians and cancer research testing to biopharma companies, although their main clinical cancer indications differ. Personalis's testing business with drug developers is a useful comparison for demand behind Adaptive's research revenue.
NeoGenomics, Inc. overlaps Adaptive's clonoSEQ market by offering blood-cancer monitoring through flow cytometry; both sell oncology laboratory testing to oncologists and pharmaceutical companies.
Guardant Health and Adaptive sell cancer monitoring tests and testing services to overlapping clinical and biopharma customer groups, but Guardant's main clinical uses differ from clonoSEQ's lymphoid cancers. Guardant's biopharma and data revenue offers a comparison for drug-company demand, rather than a direct read on clonoSEQ clinical testing.
Adaptive depends on Illumina for the machines, proprietary reagents and maintenance needed to process diagnostic and research samples. Watch supplies for its NextSeq and NovaSeq X Plus systems: replacing those reagents could require new equipment and assay revalidation, delaying sample processing.
Autolus Therapeutics plc pays Adaptive to analyze samples from patients with relapsed or refractory B-cell acute lymphoblastic leukemia, linking Adaptive's testing business to Autolus's therapy program. Watch regulatory and commercial milestones tied to use of the assay; Autolus said no further milestones were probable as of December 31, 2025.
Pfizer Inc. licenses Adaptive's immune-receptor data and uses its T-cell capabilities to find rheumatoid arthritis drug targets, but Pfizer alone controls subsequent clinical development and commercialization. For Adaptive, watch whether Pfizer advances those targets into therapeutic development, not just whether datasets are delivered.
Tempus AI and Adaptive compete for healthcare providers' testing budgets and life-sciences customers' research spending, selling molecular cancer tests and proprietary biological data. Watch Tempus's oncology testing and data-licensing business for comparisons with clonoSEQ and Adaptive's immune-data offerings.
NeoGenomics, Inc. earningsNEO
NeoGenomics’ report will show whether demand for oncology testing is holding up, including flow-cytometry testing for blood cancers that competes with clonoSEQ.
Look at NeoGenomics’ oncology testing activity and any separately reported blood-cancer testing. If that activity holds up, clinicians are still using a testing approach that competes with clonoSEQ; if it weakens, competitive pressure may ease. NeoGenomics covers a broader business, so its overall results do not establish how clonoSEQ itself is performing. The takeaway is the environment for competing tests, not Adaptive’s own test demand.
Illumina Inc earningsILMN
Illumina’s report and supply commentary offer clues about the sequencing systems, proprietary reagents and maintenance that Adaptive relies on to process samples.
Watch Illumina’s comments on sequencing-system and reagent demand, supply, and support. Steady supply and maintenance would lower concern about disruption to Adaptive’s use of NextSeq and NovaSeq X Plus systems; signs of supply or service problems would raise the risk of processing delays or costly replacement and validation. Illumina’s overall results cannot confirm that Adaptive’s specific reagents are available, so the conclusion is about supply-chain risk, not proof that Adaptive has been affected.
Personalis, Inc. earningsPSNL
Personalis’ report will show whether drug developers are buying cancer-testing services, a useful demand comparison for Adaptive’s MRD research testing.
Look at Personalis’ testing business for drug developers and distinguish it from clinical testing. Steady or rising activity would suggest that drug companies are still buying cancer-testing services, a supportive demand signal for Adaptive’s MRD research testing; weakness would flag possible pressure on that customer spending. The companies serve different cancer indications and offer different services, so the conclusion is about the direction of customer demand, not Adaptive’s own orders.
Adaptive Biotechnologies Corporation earningsThis company
Adaptive Biotechnologies’ report will show whether more clonoSEQ tests are translating into clinical MRD service revenue, rather than growth relying mainly on other revenue.
Read clonoSEQ test volume alongside MRD service revenue. If both rise, greater clinical use is translating into revenue; if tests rise but service revenue does not keep pace, volume alone does not show that reimbursement and revenue conversion are working. Separate Immune Medicine service and licensing revenue from collaboration revenue, which may include recognition of cash deferred earlier. The conclusion is whether growth is coming through ongoing clinical testing and services, rather than other revenue items.
Natera, Inc. earningsNTRA
Natera’s report will offer a read on adoption and reimbursement for cancer MRD testing, a market signal for clonoSEQ’s broader environment.
Read Signatera adoption alongside reimbursement and payment information. Rising use with steady payment support would show that clinicians and payers continue to accept cancer MRD testing; weaker adoption or reimbursement would point to pressure on demand or payment. Signatera and clonoSEQ address different cancers, so Natera’s results do not prove clonoSEQ coverage or revenue. The takeaway is whether the broader MRD market environment is supportive.
